CPRX Valuation

Catalyst Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

20.900

-0.11(-0.524%)1D

Overview
Forecast
Valuation
Earnings

CPRX Relative Valuation

CPRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CPRX is overvalued; if below, it's undervalued.

Historical Valuation

Catalyst Pharmaceuticals Inc (CPRX) is now in the Fair zone, suggesting that its current forward PE ratio of 15.10 is considered Fairly compared with the five-year average of 13.71. The fair price of Catalyst Pharmaceuticals Inc (CPRX) is between 13.43 to 23.34 according to relative valuation methord.

Relative Value

Fair Zone

13.43-23.34

Current Price：20.98

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

3.26

P/B

Median3y

4.33

Median5y

3.81

10.43

FCF Yield

Median3y

3.62

Median5y

6.03

Competitors Valuation Multiple

The average P/S ratio for CPRX's competitors is 31.46, providing a benchmark for relative valuation. Catalyst Pharmaceuticals Inc Corp (CPRX) exhibits a P/S ratio of 4.61, which is -85.33% above the industry average. Given its robust revenue growth of 43.56%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CPRX.O

Catalyst Pharmaceuticals Inc

4.61

Average P/S: 31.46

43.56%